Clinical Data Shows Significant Improvements in Lymphedema Treatment

ATLANTA, Oct. 7, 2026 /CourierPR/ -- Celltaxis, a clinical-stage biotechnology company dedicated to developing novel therapies for lymphatic diseases, has announced the publication of clinical data in the peer-reviewed journal Scientific Reports.

The study, conducted at the Stanford Center for Lymphatic and Venous Disorders at Stanford University School of Medicine, evaluated 12 months of once-daily 100 mg oral treatment with acebilustat in patients with chronic Stage II lower-extremity lymphedema. The data showed a statistically significant reduction in lymphedematous limb volume, with an average decrease of approximately one liter over 12 months. Significant reductions were evident as early as three months.

The research also reported measurable decreases in skin thickness, with the most prominent effects observed at the proximal calf (-1.1 mm, P = 0.004) and midthigh (-1.6 mm, P < 0.001). Additionally, the study found improvements in tissue architecture and extracellular fluid content, as indicated by ultrasonographic analysis and bioimpedance measurements. These changes were supported by a reduction in R0 13.8 [95% C.I.: 1.8 to 25.8], P = 0.03.

The publication provides important clinical evidence supporting Celltaxis' novel therapeutic approach, which targets the LTA4H/LTB4 inflammatory pathway to promote lymphatic repair.

Lymphedema, a chronic, progressive inflammatory disease affecting approximately 10 million Americans and an estimated 250 million people worldwide, is caused by damage to or dysfunction of the lymphatic system. When lymphatic vessels become damaged, tissue fluid drainage is impaired, leading to chronic inflammation, swelling, tissue remodeling, adipose deposition, fibrosis, reduced mobility, and diminished quality of life.

The findings from this study represent a significant milestone for Celltaxis, as they provide evidence that the pathogenetic mechanisms driving lymphatic dysfunction can be therapeutically targeted. The company's Phase 2 program is focused on a highly selective LTA4H inhibitor that facilitates lymphatic repair.

Growing scientific evidence has shown that excessive leukotriene B4 (LTB4) signaling suppresses biological pathways responsible for repairing and regenerating damaged lymphatic vessels, and LTB4 has been established, both clinically and non-clinically, as a key driver of lymphedema. By selectively inhibiting LTA4H, the enzyme responsible for producing LTB4, Celltaxis' technology is designed to reduce pathological inflammatory signaling and restore the body's natural lymphatic repair processes, addressing an underlying driver of lymphatic dysfunction rather than simply managing its symptoms.

Key findings from the published data include: - Significant Reduction in Limb Volume: Once-daily oral treatment with the LTA4H inhibitor was associated with an average reduction of approximately one liter in lymphedematous limb volume over 12 months (-1,012.3 mL [95% C.I.: -1457.9 to -565.9], P < 0.0001). Significant reductions were evident as early as three months. - Measurable Decrease in Skin Thickness: Caliper and ultrasonographic evaluations demonstrated significant reductions in skin thickness, with the most prominent effects observed at the proximal calf (-1.1 mm, P = 0.004) and midthigh (-1.6 mm, P < 0.001). - Improved Tissue Architecture & Body Composition Analysis: Ultrasonographic analysis and bioimpedance measurements revealed structural changes supporting favorable impact on affected tissue architecture and extracellular fluid accumulation (R0 13.8 [95% C.I.: 1.